Exploring the landscape of stem cell research for Alzheimer's disease: A bibliometric analysis spanning 2002–2021

doi:10.5246/jcps.2023.10.066

Abstract

Abstract:

An increasing number of research on stem cells and Alzheimer's disease (AD) has been accomplished, making stem cells the research hotspot in the field. This study was conducted to identify the hotspots and trends of research related to stem cells and AD through a bibliometric analysis. A systematic search was performed in the Web of Science Core Collection database for relevant articles published from 2002 to 2021. Data were analyzed through Cite Space and VOS viewer. Stem cell research into AD covered 94 countries/regions, with a total of 3629 institutions participating, and showed an increasing trend every year, with the United States and China being the major countries studied. Takahashi’s team cultured the induced pluripotent stem cells for the first time, which became the source of many researchers’ theories. The University of California System is the organization with the most impact on research results. Plos One is the most popular journal. Maiese found that SIRT1 is the treatment target of AD, and his research results are the most. Research interests include brain, dentate gyrus, amyloid-beta, oxidative stress, neurodegeneration, inflammation, pluripotent stem cells, neutralistic stem cells, and microglia. Our study revealed the global research trend of stem cells in AD. At present, the research hotspot is the research of induced pluripotent stem cell models in AD. It provides important information and reference for researchers in this field.

Key words: Stem cells, Alzheimer's disease, Bibliometrics, Research hotspots

Supporting:

Fangcun Li, Ding Zhang, Zi Li, Zhaomeng Hou, Wei Chen, Jie Chen, Yueqiang Hu. Exploring the landscape of stem cell research for Alzheimer's disease: A bibliometric analysis spanning 2002–2021[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(10): 813-834.

Figures/Tables 21

Table 1. Top 10 countries/regions publications related to stem cells and AD.

Table 2. Top 10 institutions in the number of published articles related to stem cells and AD.

Table 3. Top 10 productive journals related to stem cells and AD.

Table 4. Top 10 co-cited journals in terms of citation frequency related to stem cells and AD.

Table 5. Top 10 productive authors in research related to stem cells and AD.

Table 6. Top 10 co-cited authors in research related to stem cells and AD.

Table 7. Top 10 co-cited references on research related to stem cells and AD.

Table 8. Top 30 high-frequency keywords in research related to stem cells and AD.

References 72

[1]	Kim, H.J.; Cho, K.R.; Jang, H.; Lee, N.K.; Jung, Y.H.; Kim, J.P.; Lee, J.I.; Chang, J.W.; Park, S.; Kim, S.T.; Moon, S.W.; Seo, S.W.; Choi, S.J.; Na, D.L. Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: a phase I clinical trial. Alzheimers Res. Ther. 2021, 13, 154.
[2]	Ma, N.; Ji, C. Acetylcholine ameliorates inflammatory microenvironment via regulating the balance of IL-1β/IL-1RA. J. Chin. Pharm. Sci. 2023, 32, 260.
[3]	Qin, C.A.; Li, Y.N.; Wang, K.W. Novel balance mechanism participates in stem cell therapy to alleviate neuropathology and cognitive impairment in animal models with Alzheimer’s disease. Cells. 2021, 10, 2757.
[4]	Madani Neishaboori, A.; Eshraghi, A.; Tasouji Asl, A.; Shariatpanahi, M.; Yousefifard, M.; Gorji, A. Adipose tissue-derived stem cells as a potential candidate in treatment of Alzheimer’s disease: a systematic review on preclinical studies. Pharmacol. Res. Perspect. 2022, 10, e00977.
[5]	Qin, C.; Wang, K.W.; Zhang, L.; Bai, L. Stem cell therapy for Alzheimer’s disease: an overview of experimental models and reality. Anim. Models Exp. Med. 2022, 5, 15–26.
[6]	Vasic, V.; Barth, K.; Schmidt, M.H.H. Neurodegeneration and neuro-regeneration-alzheimer’s disease and stem cell therapy. Int. J. Mol. Sci. 2019, 20, 4272.
[7]	Cone, A.S.; Yuan, X.G.; Sun, L.; Duke, L.C.; Vreones, M.P.; Carrier, A.N.; Kenyon, S.M.; Carver, S.R.; Benthem, S.D.; Stimmell, A.C.; Moseley, S.C.; Hike, D.; Grant, S.C.; Wilber, A.A.; Olcese, J.M.; Meckes, D.G. Mesenchymal stem cell-derived extracellular vesicles ameliorate Alzheimer’s disease-like phenotypes in a preclinical mouse model. Theranostics. 2021, 11, 8129–8142.
[8]	Hu, Y.; Zhang, Y.T. In vitro studies on the multi-target anti-Alzheimer activities of berberine-like alkaloids from Coptidis Rhizoma. J. Chin. Pharm. Sci. 2014, 23, 385–392.
[9]	Arranz, A.M.; De Strooper, B. The role of astroglia in Alzheimer’s disease: pathophysiology and clinical implications. Lancet Neurol. 2019, 18, 406–414.
[10]	Carter, S.F.; Herholz, K.; Rosa-Neto, P.; Pellerin, L.; Nordberg, A.; Zimmer, E.R. Astrocyte biomarkers in Alzheimer’s disease. Trends Mol. Med. 2019, 25, 77–95.
[11]	Najm, R.; Jones, E.A.; Huang, Y.D. Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease. Mol. Neurodegener. 2019, 14, 1–13.
[12]	Marcum, Z.A.; Keene, C.D.; Larson, E.B. Leveraging neuropathological data in pharmacoepidemiology: a promising approach for dementia prevention? Pharmacoepidemiol. Drug Saf. 2021, 30, 1–3.
[13]	Leng, Z.K.; Zhu, R.J.; Hou, W.; Feng, Y.M.; Yang, Y.L.; Han, Q.; Shan, G.L.; Meng, F.Y.; Du, D.S.; Wang, S.H.; Fan, J.F.; Wang, W.J.; Deng, L.C.; Shi, H.B.; Li, H.J.; Hu, Z.J.; Zhang, F.C.; Gao, J.M.; Liu, H.J.; Li, X.X.; Zhao, Y.Y.; Yin, K.; He, X.J.; Gao, Z.C.; Wang, Y.B.; Yang, B.; Jin, R.H.; Stambler, I.; Lim, L.W.; Su, H.X.; Moskalev, A.; Cano, A.; Chakrabarti, S.; Min, K.J.; Ellison-Hughes, G.; Caruso, C.; Jin, K.L.; Zhao, R.C. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020, 11, 216.
[14]	Upadhaya, P.G.; Pulakkat, S.; Patravale, V.B. Nose-to-brain delivery: exploring newer domains for glioblastoma multiforme management. Drug Deliv. Transl. Res. 2020, 10, 1044–1056.
[15]	Rodriguez-Outeiriño, L.; Hernandez-Torres, F.; Ramirez de Acuña, F.; Rastrojo, A.; Creus, C.; Carvajal, A.; Salmeron, L.; Montolio, M.; Soblechero-Martin, P.; Arechavala-Gomeza, V.; Franco, D.; Aranega, A.E. miR-106b is a novel target to promote muscle regeneration and restore satellite stem cell function in injured Duchenne dystrophic muscle. Mol. Ther. Nucleic Acids. 2022, 29, 769–786.
[16]	Zakrzewski, W.; Dobrzyński, M.; Szymonowicz, M.; Rybak, Z. Stem cells: past, present, and future. Stem Cell Res. Ther. 2019, 10, 1–22.
[17]	Liu, X.Y.; Yang, L.P.; Zhao, L. Stem cell therapy for Alzheimer’s disease. World J. Stem Cells. 2020, 12, 787–802.
[18]	Rai, G. New insights on stem cells modeling and treatment of human diseases. Front. Biosci. 2020, 25, 1568–1599.
[19]	Pacheco-Herrero, M.; Soto-Rojas, L.O.; Reyes-Sabater, H.; Garcés-Ramirez, L.; de la Cruz López, F.; Villanueva-Fierro, I.; Luna-Muñoz, J. Current status and challenges of stem cell treatment for Alzheimer’s disease. J. Alzheimer’s Dis. 2021, 84, 917–935.
[20]	Hayashi, Y.; Lin, H.T.; Lee, C.C.; Tsai, K.J. Effects of neural stem cell transplantation in Alzheimer’s disease models. J. Biomed. Sci. 2020, 27, 1–11.
[21]	Si, Z.Z.; Wang, X.D. Stem cell therapies in Alzheimer’s disease: applications for disease modeling. J. Pharmacol. Exp. Ther. 2021, 377, 207–217.
[22]	Ma, D.; Guan, B.; Song, L.; Liu, Q.; Fan, Y.; Zhao, L.; Wang, T.; Zhang, Z.; Gao, Z.; Li, S.; Xu, H. A Bibliometric Analysis of Exosomes in Cardiovascular Diseases From 2001 to 2021. Front. Cardiovasc. Med. 2021, 8, 734514.
[23]	Wang, S.; Zhou, H.P.; Zheng, L.; Zhu, W.L.; Zhu, L.N.; Feng, D.; Wei, J.; Chen, G.N.; Jin, X.H.; Yang, H.; Shi, X.; Lv, X. Global trends in research of macrophages associated with acute lung injury over past 10 years: a bibliometric analysis. Front. Immunol. 2021, 12, 669539.
[24]	Ding, Z.B.; Jiang, N.; Yang, T.; Han, H.X.; Hou, M.M.; Kumar, G.; Wu, Y.G.; Song, L.J.; Li, X.Y.; Ma, C.G.; Su, Y.B. Mapping the research trends of astrocytes in stroke: a bibliometric analysis. Front. Cell Neurosci. 2022, 16, 949521.
[25]	Miao, L.; Zhang, J.; Zhang, Z.; Wang, S.; Tang, F.; Teng, M.; Li, Y. A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021. Front. Immunol. 2022, 13, 840956.
[26]	Chen, B.; Fu, Y.; Song, G.; Zhong, W.; Guo, J. Research Trends and Hotspots of Exercise for Alzheimer’s Disease: A Bibliometric Analysis. Front. Aging Neurosci. 2022, 14, 984705.
[27]	Zhang, Y.; Li, A.; Xiao, S.Z.; Zhong, N.Y.; Tong, W.L.; Wang, S.W.; Liu, J.M.; Liu, Z.L. A bibliometric analysis of publications on spinal cord injury treatment with glucocorticoids using VOSviewer. Front. Public Health. 2022, 10, 907372.
[28]	Fan, J.C.; Gao, Y.; Zhao, N.; Dai, R.J.; Zhang, H.L.; Feng, X.Y.; Shi, G.X.; Tian, J.H.; Chen, C.; Hambly, B.D.; Bao, S.S. Bibliometric analysis on COVID-19: a comparison of research between English and Chinese studies. Front. Public Health. 2020, 8, 477.
[29]	Ke, L.X.; Lu, C.C.; Shen, R.; Lu, T.T.; Ma, B.; Hua, Y.P. Knowledge mapping of drug-induced liver injury: a scientometric investigation (2010-2019). Front. Pharmacol. 2020, 11, 842.
[30]	Ma, C.Q.; Su, H.; Li, H.J. Global research trends on prostate diseases and erectile dysfunction: a bibliometric and visualized study. Front. Oncol. 2020, 10, 627891.
[31]	Pournader, M.; Kach, A.; Talluri, S. A review of the existing and emerging topics in the supply chain risk management literature. Decis. Sci. 2020, 51, 867–919.
[32]	Gao, Y.; Fan, K.Y.; Lai, Z.N.; Wang, C.; Li, H.Y.; Liu, Q.F. A comprehensive review of the circulation of microplastics in aquatic ecosystem using scientometric method. Environ. Sci. Pollut. Res. 2022, 29, 30935–30953.
[33]	Yeung, A.W.K.; Heinrich, M.; Kijjoa, A.; Tzvetkov, N.T.; Atanasov, A.G. The ethnopharmacological literature: an analysis of the scientific landscape. J. Ethnopharmacol. 2020, 250, 112414.
[34]	Vittori, A.; Cascella, M.; Leonardi, M.; Monaco, F.; Nocerino, D.; Cuomo, A.; Ottaiano, A.; Perri, F.; Mascilini, I.; Francia, E.; Petrucci, E.; Marinangeli, F.; Picardo, S.G. VOSviewer-based bibliometric network analysis for evaluating research on juvenile primary fibromyalgia syndrome (JPFS). Children. 2022, 9, 637.
[35]	Wang, C.Y.; Jing, H.W.; Sun, Z.Y.; Yao, J.X.; Zhang, X.Y.; Liu, T.; Wu, Y. A bibliometric analysis of primary aldosteronism research from 2000 to 2020. Front. Endocrinol. 2021, 12, 665912.
[36]	Jin, K.L.; Peel, A.L.; Mao, X.O.; Xie, L.; Cottrell, B.A.; Henshall, D.C.; Greenberg, D.A. Increased hippocampal neurogenesis in Alzheimer’s disease. Proc. Natl. Acad. Sci. USA. 2004, 101, 343–347.
[37]	Ozturk, T.; Talo, M.; Yildirim, E.A.; Baloglu, U.B.; Yildirim, O.; Rajendra Acharya, U. Automated detection of COVID-19 cases using deep neural networks with X-ray images. Comput. Biol. Med. 2020, 121, 103792.
[38]	Tu, Y.F.; Chien, C.S.; Yarmishyn, A.A.; Lin, Y.Y.; Luo, Y.H.; Lin, Y.T.; Lai, W.Y.; Yang, D.M.; Chou, S.J.; Yang, Y.P.; Wang, M.L.; Chiou, S.H. A review of SARS-CoV-2 and the ongoing clinical trials. Int. J. Mol. Sci. 2020, 21, 2657.
[39]	Maiese, K. Sirtuins: developing innovative treatments for aged-related memory loss and Alzheimer’s disease. Curr. Neurovasc. Res. 2018, 15, 367–371.
[40]	Maiese, K. Neurodegeneration, memory loss, and dementia: the impact of biological clocks and circadian rhythm. Front. Biosci. (Landmark Ed). 2021, 26, 614–627.
[41]	Maiese, K. Nicotinamide as a foundation for treating neurodegenerative disease and metabolic disorders. Curr. Neurovascular Res. 2021, 18, 134–149.
[42]	Zhao, C.M.; Deng, W.; Gage, F.H. Mechanisms and functional implications of adult neurogenesis. Cell. 2008, 132, 645–660.
[43]	Glass, C.K.; Saijo, K.; Winner, B.; Marchetto, M.C.; Gage, F.H. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010, 140, 918–934.
[44]	Mu, Y.L.; Gage, F.H. Adult hippocampal neurogenesis and its role in Alzheimer’s disease. Mol. Neurodegener. 2011, 6, 85.
[45]	Mertens, J.; Herdy, J.R.; Traxler, L.; Schafer, S.T.; Schlachetzki, J.C.M.; Böhnke, L.; Reid, D.A.; Lee, H.; Zangwill, D.; Fernandes, D.P.; Agarwal, R.K.; Lucciola, R.; Zhou-Yang, L.; Karbacher, L.; Edenhofer, F.; Stern, S.; Horvath, S.; Paquola, A.C.M.; Glass, C.K.; Yuan, S.H.; Gage, F.H. Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer’s patients. Cell Stem Cell. 2021, 28, 1533–1548.e6.
[46]	Lazzari, C.; McAleer, S.; Rabottini, M. The assessment of interprofessional practice in mental health nursing with ethnographic observation and social network analysis: a confirmatory and bibliometric network study using VOSviewer. Riv Psichiatr. 2022, 57, 115–122.
[47]	Liu, S.J.; Gao, Q.H.; Deng, Y.J.; Zen, Y.; Zhao, M.; Guo, J. Knowledge domain and emerging trends in chronic prostatitis/chronic pelvic pain syndrome from 1970 to 2020: a scientometric analysis based on VOSviewer and CiteSpace. Ann. Palliat. Med. 2022, 11, 1714–1724.
[48]	Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002, 297, 353–356.
[49]	Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006, 126, 663–676.
[50]	Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007, 131, 861–872.
[51]	Lancaster, M.A.; Renner, M.; Martin, C.A.; Wenzel, D.; Bicknell, L.S.; Hurles, M.E.; Homfray, T.; Penninger, J.M.; Jackson, A.P.; Knoblich, J.A. Cerebral organoids model human brain development and microcephaly. Nature. 2013, 501, 373–379.
[52]	Blurton-Jones, M.; Kitazawa, M.; Martinez-Coria, H.; Castello, N.A.; Müller, F.J.; Loring, J.F.; Yamasaki, T.R.; Poon, W.W.; Green, K.N.; LaFerla, F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. USA. 2009, 106, 13594–13599.
[53]	Yagi, T.; Ito, D.; Okada, Y.; Akamatsu, W.; Nihei, Y.; Yoshizaki, T.; Yamanaka, S.; Okano, H.; Suzuki, N. Modeling familial Alzheimer’s disease with induced pluripotent stem cells. Hum. Mol. Genet. 2011, 20, 4530–4539.
[54]	Israel, M.A.; Yuan, S.H.; Bardy, C.; Reyna, S.M.; Mu, Y.L.; Herrera, C.; Hefferan, M.P.; Van Gorp, S.; Nazor, K.L.; Boscolo, F.S.; Carson, C.T.; Laurent, L.C.; Marsala, M.; Gage, F.H.; Remes, A.M.; Koo, E.H.; Goldstein, L.S.B. Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells. Nature. 2012, 482, 216–220.
[55]	Choi, S.H.; Kim, Y.H.; Hebisch, M.; Sliwinski, C.; Lee, S.; D'Avanzo, C.; Chen, H.C.; Hooli, B.; Asselin, C.; Muffat, J.; Klee, J.B.; Zhang, C.; Wainger, B.J.; Peitz, M.; Kovacs, D.M.; Woolf, C.J.; Wagner, S.L.; Tanzi, R.E.; Kim, D.Y. A three-dimensional human neural cell culture model of Alzheimer’s disease. Nature. 2014, 515, 274–278.
[56]	Ejaz, H.; Zeeshan, H.M.; Ahmad, F.; Bukhari, S.N.A.; Anwar, N.; Alanazi, A.; Sadiq, A.; Junaid, K.; Atif, M.; Abosalif, K.O.A.; Iqbal, A.; Hamza, M.A.; Younas, S. Bibliometric analysis of publications on the omicron variant from 2020 to 2022 in the scopus database using R and VOSviewer. Int. J. Environ. Res. Public Health. 2022, 19, 12407.
[57]	Song, L.X.; Zhang, J.; Ma, D.; Fan, Y.X.; Lai, R.M.; Tian, W.D.; Zhang, Z.H.; Ju, J.Q.; Xu, H. A bibliometric and knowledge-map analysis of macrophage polarization in atherosclerosis from 2001 to 2021. Front. Immunol. 2022, 13, 910444.
[58]	Wei, N.M.; Hu, Y.H.; Liu, G.X.; Li, S.Y.; Yuan, G.Z.; Shou, X.T.; Zhang, X.S.; Shi, J.J.; Zhai, H.Q. A bibliometric analysis of familial hypercholesterolemia from 2011 to 2021. Curr. Probl. Cardiol. 2023, 48, 101151.
[59]	Li, X.P.; Wei, W.; Wang, Y.; Wang, Q.; Liu, Z.B. Global trend in the research and development of acupuncture treatment on Parkinson’s disease from 2000 to 2021: a bibliometric analysis. Front. Neurol. 2022, 13, 906317.
[60]	Shao, B.; Qin, Y.F.; Ren, S.H.; Peng, Q.F.; Qin, H.; Wang, Z.B.; Wang, H.D.; Li, G.M.; Zhu, Y.L.; Sun, C.L.; Zhang, J.Y.; Li, X.; Wang, H. Structural and temporal dynamics of mesenchymal stem cells in liver diseases from 2001 to 2021: a bibliometric analysis. Front. Immunol. 2022, 13, 859972.
[61]	Raja, W.K.; Mungenast, A.E.; Lin, Y.T.; Ko, T.; Abdurrob, F.; Seo, J.; Tsai, L.H. Self-organizing 3D human neural tissue derived from induced pluripotent stem cells recapitulate Alzheimer’s disease phenotypes. PLoS One. 2016, 11, e0161969.
[62]	Keren-Shaul, H.; Spinrad, A.; Weiner, A.; Matcovitch-Natan, O.; Dvir-Szternfeld, R.; Ulland, T.K.; David, E.; Baruch, K.; Lara-Astaiso, D.; Toth, B.; Itzkovitz, S.; Colonna, M.; Schwartz, M.; Amit, I. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell. 2017, 169, 1276–1290.e17.
[63]	Heneka, M.T.; Carson, M.J.; El Khoury, J.; Landreth, G.E.; Brosseron, F.; Feinstein, D.L.; Jacobs, A.H.; Wyss-Coray, T.; Vitorica, J.; Ransohoff, R.M.; Herrup, K.; Frautschy, S.A.; Finsen, B.; Brown, G.C.; Verkhratsky, A.; Yamanaka, K.; Koistinaho, J.; Latz, E.; Halle, A.; Petzold, G.C.; Town, T.; Morgan, D.; Shinohara, M.L.; Perry, V.H.; Holmes, C.; Bazan, N.G.; Brooks, D.J.; Hunot, S.; Joseph, B.; Deigendesch, N.; Garaschuk, O.; Boddeke, E.; Dinarello, C.A.; Breitner, J.C.; Cole, G.M.; Golenbock, D.T.; Kummer, M.P. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015, 14, 388–405.
[64]	Selkoe, D.J.; Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25years. EMBO Mol. Med. 2016, 8, 595–608.
[65]	Muffat, J.; Li, Y.; Yuan, B.B.; Mitalipova, M.; Omer, A.; Corcoran, S.; Bakiasi, G.; Tsai, L.H.; Aubourg, P.; Ransohoff, R.M.; Jaenisch, R. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat. Med. 2016, 22, 1358–1367.
[66]	Muratore, C.R.; Rice, H.C.; Srikanth, P.; Callahan, D.G.; Shin, T.; Benjamin, L.N.P.; Walsh, D.M.; Selkoe, D.J.; Young-Pearse, T.L. The familial Alzheimer’s disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. Hum. Mol. Genet. 2014, 23, 3523–3536.
[67]	Qian, X.Y.; Nguyen, H.N.; Song, M.M.; Hadiono, C.; Ogden, S.C.; Hammack, C.; Yao, B.; Hamersky, G.R.; Jacob, F.; Zhong, C.; Yoon, K.J.; Jeang, W.; Lin, L.; Li, Y.J.; Thakor, J.; Berg, D.A.; Zhang, C.; Kang, E.; Chickering, M.; Nauen, D.; Ming, G.L. Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure. Cell. 2016, 165, 1238–1254.
[68]	Kim, H.J.; Seo, S.W.; Chang, J.W.; Lee, J.I.; Kim, C.H.; Chin, J.; Choi, S.J.; Kwon, H.; Yun, H.J.; Lee, J.M.; Kim, S.T.; Choe, Y.S.; Lee, K.H.; Na, D.L. Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: a phase 1 clinical trial. Alzheimer’s Dement. 2015, 1, 95–102.
[69]	Shin, E. Clinical trials of stem cell therapy in Japan: the decade of progress under the national program. J. Clin. Med. 2022, 11, 7030.
[70]	Xie, X.K.; Chen, J.; Shu, Z.Y. From strict moral standards to ethical neutrality: a policy-guided shift in the patentability of human embryonic stem cells in China. Stem Cell Res. Ther. 2020, 11, 1–8.
[71]	Allum, N.; Allansdottir, A.; Gaskell, G.; Hampel, J.; Jackson, J.; Moldovan, A.; Priest, S.; Stares, S.; Stoneman, P. Religion and the public ethics of stem-cell research: attitudes in Europe, Canada and the United States. PLoS One. 2017, 12, e0176274.
[72]	Ullah, M.; Liu, D.D.; Thakor, A.S. Mesenchymal stromal cell homing: mechanisms and strategies for improvement. iScience. 2019, 15, 421–438.